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Abstract
Rationale—Metabolic syndrome, inflammatory and vascular injury markers measured in serum 
after WTC exposures predict abnormal FEV1. We hypothesized that elevated LPA levels predict 
FEV1<LLN.
Methods—Nested case-control study of WTC-exposed firefighters. Cases had FEV1<LLN. 
Controls derived from the baseline cohort. Demographics, pulmonary function, serum lipids, LPA 
and ApoA1 were measured.
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Results—LPA and ApoA1 levels were higher in cases than controls and predictive of case status. 
LPA increased the odds by 13% while ApoA1 increased the odds by 29% of an FEV1<LLN in a 
multivariable model.
Conclusions—Elevated LPA and ApoA1 are predictive of a significantly increased risk of 
developing an FEV1<LLN.
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INTRODUCTION
The destruction of the World Trade Center (WTC) complex led to the exposure of thousands 
of subjects to particulates and the products of combustion. The intense particulate matter 
(PM) exposure at the WTC site overwhelmed the lung’s normal protective defenses. 
Respiratory compromise after WTC-PM exposure has been documented in FDNY rescue 
workers, (Prezant et al., 2002, Banauch et al., 2005, Banauch et al., 2006, Feldman et al., 
2004, Banauch et al., 2003, Felipe et al., 2011, Aldrich et al., 2010) other exposed workers 
(Herbert et al., 2006) and lower Manhattan residents.(Reibman et al., 2005, 2002a, 2002b) 
Some individuals subsequently developed abnormal lung function while others improved. It 
is this dichotomous outcome and identifying predictive biomarkers that has been the focus 
of our recent work.
Our group has published that mediators of metabolic syndrome, inflammation and vascular 
injury in early serum samples are predictive of lung function outcome in a longitudinally 
followed never smoking World Trade Center exposed FDNY cohort.(Nolan et al., 2012) 
Development of lung dysfunction following particulate exposure is a major health concern 
worldwide. The prevalence of metabolic syndrome is high in industrialized nations and is 
rapidly increasing in developing nations where high ambient particulates are also a 
tremendous health concern.(Chen and Schwartz, 2008) The interaction of these two 
disorders is a topic of considerable importance.
Nearly half of chronic obstructive pulmonary disease (COPD) patients demonstrate the 
presence of one or more components of metabolic derangement. Lipids are key components 
of metabolic syndrome and their metabolites have been linked to pulmonary inflammation 
and subsequent airflow obstruction.(Tiengo et al., 2008) We also know that statin therapy 
reduced airspace inflammatory cells and Th2 cytokine production in murine allergic asthma. 
(Yeh and Huang, 2004, McKay et al., 2004) Simvastatin inhibited lung parenchymal 
destruction and peribronchial and perivascular inflammatory cell infiltration in a murine 
model of smoking-induced emphysema.(Lee et al., 2005) In asthmatics, statin therapy is 
associated with reduced leukocytes and leukotrienes in sputum and improvement in FEV1.
(Hothersall et al., 2008, Cowan et al., 2010) Subjects with COPD treated with statins had 
reduced FEV1 decline, decreased intubations and decreased mortality.(Blamoun et al., 2008, 
Soyseth et al., 2007) There are also data that suggest a relationship between serum total and 
non-HDL cholesterol and having asthma.(Fessler et al., 2009) Therefore not only are lipids 
biologically active in the development of lung disease but they are also plausible therapeutic 
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targets. However, the systemic inflammatory effects of lipids, their subsequent end-organ 
effects and the mechanism of lipid-induced pulmonary inflammation are poorly understood.
Low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides (Trig) are 
routinely available biomarkers of vascular disease and are components of metabolic 
syndrome. Our group has recently shown that dyslipidemia is a predictor of developing 
World Trade Center-lung injury (WTC-LI). As a logical extension of our earlier work we 
therefore turned our attention to the biological active lipids, LPA (an LDL derivative) and 
ApoA1 (a component of HDL). We hypothesized that LPA and ApoA1, a known mediator 
of LPA, predict the development of World Trade Center-LI. In a nested case control study 
we show that increased serum LPA and ApoA1 levels predict the development of an 
abnormal FEV1 in our WTC-PM exposed firefighters. Some of the results of these studies 
have been previously reported in the form of an abstract.(Cho et al., 2013)
METHODS
Study Design
As part of the first medical monitoring exam (MME) post-9/11, all participants received 
pulmonary function testing (PFT) and serum samples were collected and banked in a 
biorepository. Firefighters who presented with pulmonary symptoms were referred to 
subspecialty pulmonary evaluation (SPE) between 9/12/2001 and 3/10/2008. The baseline 
cohort was derived from the 1,720 exposed symptomatic workers who needed subspecialty 
pulmonary evaluation (SPE) and treatment within 6.5 years of 9/11/2001.(Weiden et al., 
2012, Naveed et al., 2012) We performed a nested case-control study on a homogeneous 
baseline cohort of 801 subjects without prior lung disease and without tobacco use as a lung 
disease confounder. We specifically excluded all subjects who ever reported smoking on any 
of their yearly monitoring visits. Cases and controls were both drawn from this baseline 
cohort. Cases of WTC-LI were identified as the 100 (62 of whom had all final model 
parameters) that had the lowest FEV1 at the time of SPE. Specifically, cases were defined as 
being in the bottom octile of FEV1 % predicted at SPE. The FEV1 % predicted of the cases 
was below the lower limit of normal (LLN) as calculated by NHANES III. The cohort 
control (N = 171) was randomly selected from the baseline cohort after stratification on BMI 
and FEV1 at MME. The controls are all individuals in the random sample cohort control 
who did not meet criteria to be a World Trade Center-LI case (n=153). Controls with all 
final model parameters were 111/153. All subjects signed informed Institutional Review 
Board-approved consent at the time of enrollment allowing analysis of their information and 
samples for research. This study has been approved by the Institutional Review Boards of 
Montefiore Medical Center; #07-09-320 and New York University; #11-00439).
Demographics
Age, race and years of service at FDNY were obtained from the FDNY-WTC-monitoring 
database. BMIs were calculated from height and weight measured at the time of MME and 
SPE. Degree of exposure was self-reported at the first FDNY-WTC-monitoring and was 
categorized using the FDNY-World Trade Center Exposure Intensity Index (Arrival Time): 
1. Present on the morning of 9/11/2001; 2. Arrived between afternoon on 9/11/2001 and 
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9/12/2001.(Weiden et al., 2010) Those arriving after day three were excluded from analysis 
as a result of their low numbers in this sample.(Longo et al., 2011) In addition, medication 
histories were obtained by reviewing clinical and electronic medication records. Subject 
were considered to have received pulmonary specific treatment if they had ever received 
either a short acting beta-agonist, long acting beta-agonist or inhaled corticosteroid. In 
addition, we considered a subject to have received lipid-lowering therapy if they were on 
any statin at any time.
Serum Sampling
Blood drawn at the first post-9/11 FDNY-WTC monitoring exam was allowed to stand for 
one hour at room temperature before being centrifuged at 1,800g for ten minutes. Serum was 
stored at −80°C (Bio-Reference Laboratories, Inc. Elmwood Park, NJ). Serum was thawed 
once at 4°C and assayed using LPA Elisa (Echelon, USA) and Apolipoprotein Plex 
(Millipore, USA) according to manufacturer’s instructions on a Luminex 200IS (Luminex 
Corporation, Austin, TX). Data were analyzed using Graphpad Prism V (San Diego, USA) 
and MasterPlexQT (Mirabio, USA). Other measures of inflammation such as white blood 
cell count (WBC) and differential were obtained from the medical records at the time of 
MME serum sampling.
Statistical Analysis
We tested normality using the Shapiro-Wilk test and Q-Q plots. Data are expressed as 
median (interquartile range, IQR) or Odds Ratio (95% confidence interval), unless otherwise 
stated. A two-sided p-value less than 0.05 were considered significant. All analyses were 
performed with STATA/SE version 12.1 (StataCorp LP, College Station, TX) and SPSS 
version 20(IBM, USA). We used Wilcoxon rank sum test for between group comparisons, 
as appropriate. Chi-squared test was used to determine significance of categorical variable.
Lipid Predictors of WTC-LI Model Building and Validation
Given the dichotomous outcome of normal and abnormal FEV1 we tested if serum 
biomarkers predicted airflow obstruction using logistic regression. Variables identified as 
potential confounders and those with a P value < 0.2 in univariable analysis were included in 
the multivariable logistic regression model. The Hosmer-Lemeshow goodness-of-fit test was 
used to assess calibration of the final model. The model discrimination was evaluated using 
the receiver operating characteristic area under the curve (AUC). Bootstrap was used to 
internally validate and confirm the robustness of the classification performance using 10,000 




FEV1 was measured starting three years prior to 9/11/2001. FEV1 is still performed at every 
FDNY-WTC-Medical Monitoring and Treatment Program (MMTP) visit, giving a 
comprehensive measure of changing lung function over time. The baseline cohort was 
derived from the symptomatic subjects enrolled in the SPE cohort if they met the inclusion 
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criteria as outlined in Figure 1 and as previously described. Derivation of 801 baseline 
cohort, 62 cases, and 111 controls from the SPE cohort with final model characteristics 
available is described in Figure 1.
Demographics of both the SPE cohort and baseline cohort were similar to sub-cohort 
controls, as previously described.(Nolan et al., 2011) Cases and controls had statistically 
similar time from 9/11 to MME and SPE, years of service, and age at 9/11. Cases had a 
similar percentage of subjects that arrived at the site on the morning of 9/11 as arrived on the 
afternoon of 9/11 till 9/12. BMI of the cases was only significantly elevated compared to 
controls at SPE, Table 1.
Lung Function and Computed Tomography (CT)-Scan Phenotyping
Lung Function—Controls had similar FEV1, forced vital capacity (FVC) and FEV1/FVC 
compared to the SPE cohort (N=1720) and baseline cohort (N=801) (data not shown). Cases 
had lower FEV1, FVC, FEV1/FVC, total lung capacity (TLC), alveolar volume (VA), 
carbon monoxide diffusing capacity (DLCO) and DLCO/VA when compared to controls at 
all-time points. Measures of airflow obstruction, including methacholine slope and 
bronchodilator response was statistically increased in the cases when compared to controls, 
Table 2. Lung function in sub-cohort controls increased from the MME to SPE (93% to 
97%) while the FEV1% predicted (FEV1%pred) of affected cases continued to decline 
between the two pulmonary function tests (78% to 72%; p<0.0001 all comparisons). Despite 
these significant differences in lung function we found that 57/62 (92%) of cases and 91/111 
(82%) of controls were receiving some pulmonary specific treatment. (Pearson’s χ2 3.188, 
p=0.074).
CT-Scan Phenotype—CT scans had been done on 38/62 cases and 61/111 controls. 
Cases had similar measures of air trapping and bronchial wall thickening as controls.
Clinical Biomarkers of Inflammation and Lipid Derangement in Cases and Controls
We used logistic regression as a tool to analyze our data (binary outcome), we indeed 
checked the linear relationship between the logit (log-odds) and the continuous variables 
following the steps described by Hosmer and Lemeshow.(Hosmer and Lemeshow, 1989) No 
transformations of the data were needed.
Univariable regression was used to identify potential predictors and confounders of case 
status. Based on the analysis, LPA, ApoA1 and, as previously showed, dyslipidemia were 
significant predictors of case status. On the other hand, HDL, LDL, triglycerides, WBC and 
cell differential were not, Table 3. LPA, ApoA1, Dyslipidemia, polymorphonuclear (PMN) 
all had a P value < 0.2 and were included in the multivariable logistic regression model. 
Even though the medians of LPA levels were similar between cases and controls, the same 
magnitude of increment (10 uM) does not behave the same in terms of LI prediction. In the 
univariable and multivariable logistic analyses per every 10uM increased in LPA the odd of 
developing LI was estimated to be 1.12 and 1.13 times larger respectively.
Despite platelet count not being significant in univariate analysis we chose to include it in 
multivariable analysis, since it is a known potential confounder of vascular disease and a 
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source of LPA. (Boucharaba et al., 2004) In addition, review of their electronic medical 
record showed that 16/111 (15%) of the control patients and 11/62 (18%) of the cases were 
taking a statin (Pearson’s χ2 0.336; p=0.56).
Inflammatory and Dyslipidemic Biomarkers Predict Decline in Lung Function
To assess the relationship between LPA and ApoA1 with the outcome of being a susceptible 
case, we fitted a multivariable logistic model adjusted for BMI at SPE, exposure intensity, 
pre-9/11 FEV1 % predicted, age on 9/11, and WTC arrival time, dyslipidemia, platelet and 
PMN count, Table 4. In the adjusted model, a 10 μM increase of LPA was associated with a 
14% increase in the odds of having WTC-LI while an increase of 1 mg/mL of ApoA1 
increased the odds of developing WTC-LI by 29%, Table 4. The interaction term was not 
significant. The change in BMI was also adjusted for in this same model and a 10 μM 
increase of LPA was associated with a 12% increase in the odds of having World Trade 
Center-LI while an increase of 1 mg/mL of ApoA1 increased the odds of developing World 
Trade Center-LI by 29%.
Model Validation—Since there is no external cohort that can be used to validate this 
model, we chose bootstrapping as an internal method to validate the models classification 
performance. We chose to use bootstrapping since it outperforms jackknife.(Steyerberg et 
al., 2001) For LPA the calculated bias was 0.0019022 (Coefficient p = 0.045) and for 
ApoA1 of 0.0342232 (Coefficient p = 0.007). Therefore, these results internally confirm the 
classification performances of the model developed above.
The Effect of LPA and ApoA1 Level on the Probability of Developing WTC-LI
To better understand the effect of LPA and ApoA1 on the probability of developing WTC-
LI, we utilized a 3-Dimensional (3D) surface plot of the 25th and 75th percentiles of both 
LPA and ApoA1, Figure 2. The chance of developing WTC-LI is shown as a probability 
isopleth. LPA and ApoA1 both show that with increasing serum levels, the probability of 
WTC-LI is increased. Specifically, LPA Axis: the probability of developing WTC-LI goes 
from 43% to 51%, when ApoA1=1.94, and from 61% to 68% when ApoA1=4.76, where 
1.94 and 4.76 are ApoA1 IQR. ApoA1 axis: the probability of developing WTC-LI goes 
from 43% to 61%, when LPA=4.3, and from 51% to 68% when LPA=27.7, Figure 2.
DISCUSSION
In this report we find that increased levels of LPA and ApoA1 in serum sampled within 6 
months of 9/11 are associated with eventual loss of FEV1 to less than LLN in the World 
Trade Center exposed FDNY firefighter cohort. These analytes were significant predictors 
when adjusted for exposure (9/11 arrival time), dyslipidemia, BMI at SPE, Pre-911 FEV1% 
predicted, platelet and PMN counts. These finding suggest the LPA and ApoA1 are 
biomarkers of World Trade Center-PM associated loss of FEV1.
Development of ventilatory dysfunction following particulate exposure is a major health 
concern worldwide. In addition, lipid derangement has also become a major health concern 
in both first and in emerging nations. Both diseases place a tremendous burden on the 
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world’s health resources. Particulate matter exposure and lipid derangements cause systemic 
inflammation, endothelial dysfunction, and subsequent end-organ damage.(Mills et al., 
2007, Tornqvist et al., 2007, Gosker et al., 2006, Gan et al., 2004)
This study focuses on cases defined by their decline in FEV1 to less than LLN at the time of 
symptomatic presentation. We believe that FEV1<LLN is the single best outcome measure 
to define lung injury in the FDNY cohort. FEV1 has been longitudinally measured starting 
three years prior to 9/11/2001 and continues to be performed at every FDNY-WTC-MMTP 
with quality controls that meet ATS criteria. This measurement has proven to be robust and 
reproducible. FEV1<LLN is widely used as an outcome in the pulmonary literature so using 
it in the WTC exposed FDNY cohort improves generalizability of our findings. Using FEV1 
as single measure of lung function could lead to non-differential misclassification since 
FEV1 is reduced in both restriction and obstruction. In prior investigation, we have observed 
that obstruction caused the vast majority of abnormal FEV1 in WTC exposed fire fighters.
(Weiden et al., 2010) While misclassification may occur when using FEV1<LLN as a single 
measure of abnormal lung function, heterogeneity of disease(s) produced by this single 
measure will bias the results toward the null. In spite of the potential for non-differential 
information bias, using FEV1<LLN has yielded strong biomarkers-disease associations.
(Weiden et al., 2013) Furthermore, our cases and controls had similar exposure as defined 
by World Trade Center arrival time, age at the time of exposure and normal FEV1 pre-911, 
relative to LLN. Finally, we had previously shown that our cohort had similar prevalence of 
lipid derangements as the larger population that it was drawn from.
Elevated LPA was observed to predict loss of FEV1 in cases of World Trade Center-LI. 
LPA is an oxidative product of low-density lipoprotein (LDL).(Siess et al., 1999)LPA is a 
phospholipid and is soluble in both cell membranes and in aqueous fluid. LPA activates 
pathways involved in vascular injury.(Moolenaar et al., 2004, Lin et al., 2010, Murph and 
Mills, 2007, Smyth et al., 2008) In addition, receptors of LPA are found in the lung. 
Specifically, the receptor for advanced glycation end-products (RAGE) has recently been 
identified as a novel mediator of LPA signaling.(Rai et al., 2012) In the lung, RAGE is 
expressed at the highest baseline level of any other organ.(Buckley and Ehrhardt, 2010) 
Pulmonary vascular injury occurs early in smoking-related COPD with pulmonary perfusion 
abnormalities and reduced blood return to the heart observed prior to development of 
abnormal FEV1.(Rodriguez-Roisin et al., 2009, Liebow, 1959) Similar pathophysiology 
likely occurs in irritant-induced COPD. Pulmonary arteriopathy was also present in over 
50% of lung biopsies from non-FDNY World Trade Center-PM exposed individuals and in 
over 70% with constrictive bronchiolitis after inhalational exposures during military service.
(Caplan-Shaw et al., 2011, King et al., 2011) Aberrant LPA signaling is implicated in 
numerous pathologies including vascular injury and tumorigenesis and the pathways 
involved are potential therapeutic targets.
ApoA1 was also found to predict loss of FEV1 as in our prior study.(Weiden et al., 2013) 
Our current study is the first to show an association between elevated ApoA1 and lung 
function loss in particulate exposure in a multianalyte model including other lipid mediators. 
ApoA1 is a mediator of LPA and a major protein in HDL and therefore their association 
with PM induced lung injury is of particular interest. ApoA1 is known to bind pro-
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inflammatory phospholipids such as LPA. In a murine cancer model, overexpression of 
ApoA1 not only led to increased survival but also to reduced levels of LPA.(Su et al., 2010) 
We know that mice with a genetic deletion of ApoA1 have increased airway resistance, 
inflammatory cell recruitment and airway collagen deposition in the steady state.(Wang et 
al., 2010) In contrast, ApoA1 is involved in the activation of protein kinase C which is 
involved in the activation of vascular and bronchial smooth muscles.(Hu et al., 1994, 
Mukherjee et al., 2013) In our analysis, the interaction term for LPA and ApoA1 was not 
significant, suggesting that the odds for developing an abnormal FEV1 due to an elevation of 
both biomarkers are likely additive, not synergistic.
This study has several limitations. Our FDNY firefighter cohort is unique as they had 
massive acute exposure to World Trade Center-PM dusts. This limits the generalizability of 
these finding to other study populations with lower level PM exposure produced by ambient 
air pollution. We did not have an unexposed control group to compare and therefore we 
could not determine the direct effect of World Trade Center-PM exposure on LPA or 
ApoA1 levels. Replication of these findings in other longitudinally followed populations 
with and without PM exposure will be important to demonstrate the generalizability of these 
findings.
This investigation shows that elevated serum LPA and ApoA1 in serum sampled within 6 
months of 9/11 predict eventual loss of FEV1 on average 6 years later. These results suggest 
these biologically active lipid mediators are involved in the pathogenesis of World Trade 
Center-PM mediated lung injury. Further investigation is required to define the mechanistic 
underpinning of LPA as a mediator of lung function loss after PM exposure. This finding 
could place LPA and ApoA1 in the center of a lipid driven inflammatory cascade.
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Figure 1. Study Design/Timeline
Symptomatic subjects in the FDNY medical monitoring exam (MME) presented for 
subspecialty pulmonary evaluation (SPE). Subjects underwent outlined studies at MME and 
SPE respectively. Baseline Cohort met the listed inclusion criteria. Cases (N=62) and 
Controls (N=111) had all final model variables available.
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Figure 2. Multi-Analyte Model as 3D Plot
Probability of developing World Trade Center-LI of both LPA and ApoA1 are represented 
when adjusting for the covariates of exposure, BMI at SPE, pre-9/11 FEV1 % predicted, 
dyslipidemia, platelet and PMN count. Plots express probability isopleths for the 
development of World Trade Center-LI with all other covariates held constant.
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Table 2
Pulmonary Function Testing and CT Phenotype
Cases Controls p‡
Pre 9/11*
FEV1 88 (82–96) 104 (92–113) <0.001
FVC 87 (80–96) 97 (88–108) <0.001
FEV1/FVC 82 (78–86) 85 (81–88) 0.001
MME*
FEV1 78 (71–88) 93 (85–100) <0.001
FVC 79 (72–88) 89 (82–95) <0.001
FEV1/FVC 82 (76–86) 84 (80–87) 0.021
SPE*
FEV1 72 (68–74) 97 (88–104) <0.001
FVC 79 (75–85) 98 (93–106) <0.001
FEV1/FVC 71 (65–77) 77 (74–81) <0.001
TLC 96 (83–105) 103 (98–109) 0.001
VA 83 (76–90) 94 (88–101) <0.001
DLCO %§ 96 (86–107) 107 (101–116) 0.001
DLCO/VA 121 (113–132) 117 (103–122) 0.044
MCT Slope|| 0.148 (0.05–1.09) 0.04 (0.02–0.10) 0.005
BD Response** 15 (8–25) 5 (2–8) <0.001
CT Findings†
Air Trapping 22/38 (58) 25/61 (41) 0.147
BWT 13/38 (34) 22/61 (36) 1.000
Definition of abbreviations: MME = medical monitoring entry; SPE = subspecialty pulmonary evaluation; MCT = methacholine challenge test; BD 
= bronchodilator response; BWT = bronchial wall thickening
*
Values Expressed as Median (Inter Quartile Range);
†
Expressed as N (%);
‡
Significance assessed by Wilcoxon Rank Sum Test or Chi-Squared Test;
§
DLCO % Predicted: Controls N=50; Cases N=42;
||
MCT Slope: Controls N=90; Cases N=30;
**
BD Response : Controls N=54; Cases=46.
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Table 3
Biomarkers and Crude OR Predicting WTC-LI
Analyte Cases* Controls* Crude OR p
LPA, μM 11.4 (5.6–42.8) 11.5 (4.0–24.2) 1.123 (1.020–1.237)** 0.018
Apo AI, mg/mL 4.36 (2.06–6.32) 2.55 (1.83–3.79) 1.237 (1.085–1.409) 0.001
HDL, mg/dL 43 (38–54) 48 (41–55) 0.985 (0.958–1.013) 0.288
LDL, mg/dL§ 133 (115–153) 131 (106–158) 1.001 (0.992–1.010) 0.852
TG, mg/dL 142 (106–226) 144 (97–246) 1.000 (0.997–1.002) 0.929
Dyslipidemia, N%† 18 (29) 17 (15) 2.262 (1.065–4.805) 0.034
WBC, × 103 6.3 (5.1–7.2) 6.2 (5.5–7.4) 0.926 (0.764–1.124) 0.437
PMN, × 103 3.5 (2.8–4.3) 3.6 (3.0–4.4) 0.787 (0.597–1.040) 0.092
Lymphocyte, Abs 1686 (1512–2200) 1760 (1508–2208) 1.000 (1.000–1.001) 0.395
Platelets 230 (219–263) 239 (206–265) 1.000 (0.993–1.007) 0.920
Definition of abbreviations: HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglyceride; WBC = white blood cell PMN = 
polymorphonuclear cell; OR = odds ratio
*
Expressed as Median (Inter Quartile Range) except for Dyslipidemia;
†




LDL Cases (n=57), Controls (n=103).
**
per 10 μM
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Table 4
Models Predicting Susceptibility to WTC -LI
Analyte OR (95 % CI)* p
Single Analyte
LPA, μM per 10 1.134 (1.020–1.261) 0.020
Apo AI, mg/mL 1.290 (1.090–1.527) 0.003
Dyslipidemia, N (%) 1.618 (0.660–3.968) 0.293
PMN, × 103 0.727 (0.521–1.015) 0.061
Platelets 1.005 (0.996–1.014) 0.318
Multi-Analytes
LPA, μM per 10 1.139 (1.020–1.272) 0.021
Apo AI, mg/mL 1.288 (1.089–1.522) 0.003
Definition of abbreviations: PMN = polymorphonuclear cell count; OR = odds ratio
*
Adjusted for Plt count, BMI at SPE, exposure intensity, pre-9/11 FEV1% predicted, PMN count, and presence of dyslipidemia (HDL<40mg/dL 
and Trig>150mg/dL); χ2 (8)=69.34, p<0.001.; Hosmer-Lemeshow (Goodness of Fit) p=0.184; AUC=0.848 (0.786–0.910)
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